title: Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.
abstract: A follow-up study has been carried out to assess the association between MTHFR polymorphisms (SNPs) and overall survival (OS) of colorectal cancer (CRC) patients. Data on 411 CRC patients after surgery were tested for the MTHFR 677C > T and 1298A > C polymorphisms. For MTHFR C677T, patients with CT genotype (HR = 1.17; 95 % CI 0.77-1.80) and those with TT genotype (HR = 1.09; 95 % CI 0.67-1.75) had no statistically significant greater risk of dying than those with wild-type genotype. For MTHFR A1298C, the HRs of AC and CC genotype were 1.09 (95 % CI 0.75-1.59) and 0.79 (95 % CI 0.48-1.29) comparing with AA genotype. In the subgroup, 183 patients received chemotherapy treatment, and the HRs of patients with CT and TT genotype were 0.93 (95 % CI 0.50-1.72) and 0.86 (95 % CI 0.44-1.68) for MTHFR C677T. For A1298C polymorphism, AC genotype (HR = 1.39; 95 % CI 0.81-2.39) and CC genotype (HR = 1.22; 95 % CI 0.75-2.00) did not show significant differences. In conclusions, no significant association was observed between the 677C > T and 1298A > C polymorphisms of MTHFR and the prognosis of colorectal cancer patients with curative resection, including all the subjects and the subgroup of chemotherapy.
authors: Department of Epidemiology, Public Health College, Harbin Medical University, 157 Baojian Street, Nangang District, Harbin, Heilongjiang, People's Republic of China.
authors: Lin
authors: L
authors: Zhu
authors: Fan
authors: F
authors: Wang
authors: FuLan
authors: F
authors: Hu
authors: YiBaina
authors: Y
authors: Wang
authors: DanDan
authors: D
authors: Li
authors: XinShu
authors: X
authors: Dong
authors: BinBin
authors: B
authors: Cui
authors: YaShuang
authors: Y
authors: Zhao
mesh_terms: D000368:Aged; D044466:Asian People / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D002681:China; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis
chemical_list: C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D005472:Fluorouracil
references: Ann Oncol. 2009 Oct;20(10):1660-6
references: 19465420
references: J Hum Genet. 2007;52(1):73-85
references: 17089070
references: Pharmacogenetics. 2004 Dec;14(12):785-92
references: 15608557
references: J Clin Oncol. 2007 Aug 20;25(24):3726-31
references: 17704422
references: Mol Diagn. 1999 Jun;4(2):95-9
references: 10462625
references: Nat Genet. 1995 May;10(1):111-3
references: 7647779
references: Mol Genet Metab. 1998 Jul;64(3):169-72
references: 9719624
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40
references: 16187112